These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Short- and long-term outcomes in diabetes patients undergoing percutaneous coronary intervention with bivalirudin compared with heparin and glycoprotein IIb/IIIA inhibitors: A meta-analysis of randomized trials. Nairooz R; Sardar P; Amin H; Chatterjee S; Helmy T; Naidu SS Catheter Cardiovasc Interv; 2015 Sep; 86(3):364-75. PubMed ID: 25914388 [TBL] [Abstract][Full Text] [Related]
6. Meta-analysis of randomized clinical trials comparing bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in patients undergoing percutaneous coronary intervention and in patients with ST-segment elevation myocardial infarction. Nairooz R; Sardar P; Amin H; Swaminathan RV; Kim LK; Chatterjee S; Feldman DN Am J Cardiol; 2014 Jul; 114(2):250-9. PubMed ID: 24890986 [TBL] [Abstract][Full Text] [Related]
7. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry. Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331 [TBL] [Abstract][Full Text] [Related]
8. Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during percutaneous coronary intervention: an analysis from the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events (REPLACE-2) trial. Rajagopal V; Lincoff AM; Cohen DJ; Gurm HS; Hu T; Desmet WJ; Kleiman NS; Bittl JA; Feit F; Topol EJ Am Heart J; 2006 Jul; 152(1):149-54. PubMed ID: 16824845 [TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. Cohen DJ; Lincoff AM; Lavelle TA; Chen HL; Bakhai A; Berezin RH; Jackman D; Sarembock IJ; Topol EJ J Am Coll Cardiol; 2004 Nov; 44(9):1792-800. PubMed ID: 15519009 [TBL] [Abstract][Full Text] [Related]
11. Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial. Stone GW; White HD; Ohman EM; Bertrand ME; Lincoff AM; McLaurin BT; Cox DA; Pocock SJ; Ware JH; Feit F; Colombo A; Manoukian SV; Lansky AJ; Mehran R; Moses JW; Lancet; 2007 Mar; 369(9565):907-19. PubMed ID: 17368152 [TBL] [Abstract][Full Text] [Related]
12. Frequency and outcomes of provisional glycoprotein IIb/IIIa blockade in patients receiving bivalirudin during percutaneous coronary intervention. Feldman DN; Wong SC; Bergman G; Minutello RM J Invasive Cardiol; 2009 Jun; 21(6):258-63. PubMed ID: 19494400 [TBL] [Abstract][Full Text] [Related]
13. Bivalirudin versus heparin and provisional GP IIb/IIIa inhibitors in patients treated for ST-segment elevation myocardial infarctions: Comparison of outcomes in a "real-world" setting. Fach A; Backhaus T; Schmucker J; Zabrocki R; Garstka D; Stehmeier J; Fiehn E; Hambrecht R; Wienbergen H J Interv Cardiol; 2017 Aug; 30(4):301-308. PubMed ID: 28593631 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bivalirudin in patients with diabetes mellitus undergoing percutaneous coronary intervention in current clinical practice. Kim LK; Wong SC; Minutello RM; Bergman G; Feldman DN J Invasive Cardiol; 2010 Mar; 22(3):94-100. PubMed ID: 20197573 [TBL] [Abstract][Full Text] [Related]
15. Impact of time to treatment on the effects of bivalirudin vs. glycoprotein IIb/IIIa inhibitors and heparin in patients undergoing primary percutaneous coronary intervention: insights from the HORIZONS-AMI trial. Schoos MM; De Luca G; Dangas GD; Clemmensen P; Ayele GM; Mehran R; Stone GW EuroIntervention; 2016 Oct; 12(9):1144-1153. PubMed ID: 27753600 [TBL] [Abstract][Full Text] [Related]
17. Direct thrombin inhibition appears to be a safe and effective anticoagulant for percutaneous bypass graft interventions. Kao J; Lincoff AM; Topol EJ; Madrid A; J Price M; Sawhney N; Teirstein PS Catheter Cardiovasc Interv; 2006 Sep; 68(3):352-6. PubMed ID: 16892428 [TBL] [Abstract][Full Text] [Related]
18. Bivalirudin versus heparin for percutaneous coronary intervention: an updated meta-analysis of randomized controlled trials. Lipinski MJ; Lhermusier T; Escarcega RO; Baker NC; Magalhães MA; Torguson R; Suddath WO; Satler LF; Pichard AD; Waksman R Cardiovasc Revasc Med; 2014; 15(6-7):315-22. PubMed ID: 25440505 [TBL] [Abstract][Full Text] [Related]
19. Bivalirudin vs heparin with or without tirofiban during primary percutaneous coronary intervention in acute myocardial infarction: the BRIGHT randomized clinical trial. Han Y; Guo J; Zheng Y; Zang H; Su X; Wang Y; Chen S; Jiang T; Yang P; Chen J; Jiang D; Jing Q; Liang Z; Liu H; Zhao X; Li J; Li Y; Xu B; Stone GW; JAMA; 2015 Apr; 313(13):1336-46. PubMed ID: 25775052 [TBL] [Abstract][Full Text] [Related]
20. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. Zeymer U; van 't Hof A; Adgey J; Nibbe L; Clemmensen P; Cavallini C; ten Berg J; Coste P; Huber K; Deliargyris EN; Day J; Bernstein D; Goldstein P; Hamm C; Steg PG Eur Heart J; 2014 Sep; 35(36):2460-7. PubMed ID: 24849104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]